V3V Share Price Performance
€0
-4.06 (-100.00%)
Price €0
Fair Value€7.50
Share Pricen/a
Is FamiCord (ETR:V3V) Using Debt In A Risky Way?
Jan 28
FamiCord AG Stock Price
- 1 Narratives written by author
- 0 Comments on narratives written by author
- 2 Fair Values set on narratives written by author
V3V Community Narratives
AN
Fair Value €7.5 28.7% undervalued intrinsic discount
Placenta Banking Expansion Will Drive Long Term Stem Cell Demand Across Europe
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
Placenta Banking Expansion Will Drive Long Term Stem Cell Demand Across Europe
Catalysts About FamiCord FamiCord operates private and public stem cell and placenta banks across Europe, storing biological samples from newborns for future therapeutic use. What are the underlying business or industry changes driving this perspective?Read more
5
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
€7.5
28.7% undervalued intrinsic discount
AnalystConsensusTarget's Fair Value
Revenue
3.73% p.a.
Profit Margin
0.066%
Future PE
23.24x
Price in 2028
€0.09
Trending Discussion
Recently Updated Narratives
AN
Placenta Banking Expansion Will Drive Long Term Stem Cell Demand Across Europe
Fair Value: €7.5 28.7% undervalued intrinsic discount
1 followerusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
FamiCord AG Key Details
Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
Apr 30, 2026
- -0.59
- 27.90%
- -11.59%
- 65.3%
About V3V
- Founded
- 1997
- Employees
- 766
- CEO
- WebsiteView website
FamiCord AG engages in the collection, processing, cryopreservation, and storage of stem cells from umbilical cord blood and tissue and postnatal tissue in Germany, Poland, Portugal, and internationally. It operates through Subgroup Vita 34 And Subgroup PBKM segments. The company produces and develops advanced therapies, genetic tests, and analyses for third parties. It also develops products and drugs based on cells, tissues, and blood for medical applications; and produces and manufactures viral vectors and CAR-T cells. In addition, the company provides biobanking services, such as freezing sperm and storage of adipose tissue and the isolation of cells from the stored materials. The company was formerly known as VITA 34 AG and changed its name to FamiCord AG in February 2025. FamiCord AG was founded in 1997 and is based in Leipzig, Germany.
